SPEX - Spherix Incorporated

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.3800
-0.0200 (-0.83%)
As of 9:30AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close2.4000
Open2.3439
Bid2.3500 x 800
Ask2.4900 x 800
Day's Range2.3800 - 2.3800
52 Week Range2.1500 - 6.5957
Volume124
Avg. Volume64,770
Market Cap5.31M
Beta (3Y Monthly)1.23
PE Ratio (TTM)2.36
EPS (TTM)1.0090
Earnings DateAug 12, 2019 - Aug 16, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date1980-05-12
1y Target Est19.00
Trade prices are not sourced from all markets
  • United States Patent & Trademark Office Allows Patent Claims for CBM BioPharma, Inc.'s Patent Application for Pancreatic Cancer Treatment
    PR Newswire22 days ago

    United States Patent & Trademark Office Allows Patent Claims for CBM BioPharma, Inc.'s Patent Application for Pancreatic Cancer Treatment

    CBM Bolsters Intellectual Property Asset Portfolio NEW YORK , June 26, 2019 /PRNewswire/ -- CBM BioPharma Inc. ("CBM") today announced that the United States Patent & Trademark Office (USPTO) ...

  • Spherix Files Preliminary Proxy Statement Advancing the Planned Acquisition of Assets of CBM BioPharma, Inc.
    PR Newswire29 days ago

    Spherix Files Preliminary Proxy Statement Advancing the Planned Acquisition of Assets of CBM BioPharma, Inc.

    NEW YORK, June 19, 2019 /PRNewswire/ -- Spherix Incorporated (SPEX) today announced that it has filed a Preliminary Proxy Statement with the Securities and Exchange Commission and announced a Special Meeting of Stockholders related to approving various items related to the proposed and previously announced acquisition of substantially all of the assets of CBM BioPharma, Inc. ("CBM"). The acquisition of the CBM assets constitutes another step in Spherix's continued transformation into an innovative pharmaceutical company with pioneering drugs and treatments focused on the development and commercialization of oncology therapeutics. CBM is a privately held pharmaceutical company with exclusive drug development rights from world renowned partners like Wake Forest University and University of Texas.

  • ACCESSWIRElast month

    Spherix Inc. (NasdaqCM: SPEX) Trading Below Book Value; Diversified Asset Base Adds Value

    MIAMI BEACH, FL / ACCESSWIRE / June 11, 2019 / Emerging stocks rarely provide more than a single compelling reason for investment. Having completed a recapitalization in May of 2019 that leaves SPEX with just over two million shares outstanding, the company's strategy to identify and invest in cutting-edge technology is already proving to be a profitable business model for SPEX.

  • ACCESSWIRElast month

    StockLab Reports: By the Numbers

    LAS VEGAS, NV / ACCESSWIRE / June 6, 2019 / In October of last year, StockLab's editorial team was introduced to Spherix Incorporated (SPEX). Frankly, it's tough to top a Spherix acquisition target restoring mobility to a nearly paralyzed rodent but last week's quarterly report perhaps rivals the moving mouse insofar as financial statements go. The Company has total assets of $11,937,000.

  • Spherix Reports First Quarter 2019 Results of $11,937,000 in Assets and $982,000 in Liabilities
    PR Newswire2 months ago

    Spherix Reports First Quarter 2019 Results of $11,937,000 in Assets and $982,000 in Liabilities

    Agreement to Acquire Assets of CBM BioPharma, Inc. In addition, the Company announced that it purchased a 20% shareholder's stake in CBM along with certain interests in DatChat, Inc. Spherix was successful in acquiring these interests in CBM at a substantial discount to CBM's valuation.  The 20% shareholder stake in CBM will give Spherix the ability to participate in any dividends declared by CBM in the future.

  • ACCESSWIRE3 months ago

    SmallCap Sentinel: One-on-One with Spherix CEO, Anthony Hayes

    ORLANDO, FL / ACCESSWIRE / April 10, 2019 / In today's issue of SmalCap Sentinel, we get the opportunity to virtually sit down with Spherix Incorporated (SPEX) CEO, Anthony Hayes. It has been an eventful year for Hayes and Spherix, much of which Hayes covered in a wide-ranging recent shareholderletter.

  • ACCESSWIRE3 months ago

    Emerging Markets Report: By Any Measure

    ORLANDO, FL / ACCESSWIRE / April 3, 2019 / By any measure, Spherix Incorporated (NASDAQ: SPEX) has had a very good year. It is not often one can say at their annual meeting that the Company posted a one-time gain of $7.5 million and p.s., our science looks like it restored mobility to a mouse paralyzed by Acute Lymphoblastic Leukemia. With Spherix now booking total assets of $13.3 million, less than 9 million shares outstanding and zero debt, CEO Anthony Hayes has likely engendered some goodwill from his shareholder base.

  • Spherix Issues Letter to Shareholders
    PR Newswire4 months ago

    Spherix Issues Letter to Shareholders

    One of the most challenging tasks as CEO is taking the vision of the Board and transferring that into meaningful value for our shareholders.  However, 2018 marked a pivotal year for our Company as we forged ahead with the vision of creating an exciting biotechnology company.  With more than $13,000,000 in assets and less than 9,000,000 in outstanding shares, we are moving Spherix in the right direction. The CBM transaction, announced in October of last year, brings to Spherix exclusive drug development rights from world-renowned partners including Wake Forest Innovations and the University of Texas at Austin.  Significant progress has already been made.

  • ACCESSWIRE4 months ago

    SmallCap Sentinel: A Gain of Uncommon Proportions

    ORLANDO, FL / ACCESSWIRE / March 13, 2019 / In the world of smaller equities, revenue, especially for emerging biotech or tech companies, can be fleeting, rare even. As such, Spherix Incorporated (SPEX) posting a one-time gain of $7.5 million in its 10-K should turn a few heads. It is notable that the $7.5 million one-time gain comes from an investment the Company and Spherex CEO Anthony Hayes made two years ago, putting $670k into a then private biotech called Hoth Therapeutics where Hayes saw potential and promise.

  • Spherix Announces Filing of its Annual Report on Form 10-K, Records $7.5 Million One Time Gain
    PR Newswire4 months ago

    Spherix Announces Filing of its Annual Report on Form 10-K, Records $7.5 Million One Time Gain

    NEW YORK , March 12, 2019 /PRNewswire/ -- Spherix Incorporated (NASDAQ: SPEX)- a technology development company committed to the fostering of innovative ideas, announced today that it has filed its Annual ...

  • 4 Stocks Join Ben Graham Net-Net Screener Friday
    GuruFocus.com4 months ago

    4 Stocks Join Ben Graham Net-Net Screener Friday

    While many investors are enjoying a lift in their stocks, the Ben Graham Screener, which finds net-nets, has been active

  • Spherix Announces Preclinical Pancreatic Cancer Treatment Study Moving Forward
    PR Newswire8 months ago

    Spherix Announces Preclinical Pancreatic Cancer Treatment Study Moving Forward

    NEW YORK, Nov. 27, 2018 /PRNewswire/ -- Spherix Incorporated (SPEX) today announced the funding of a study for KPC34, for pancreatic cancer, specifically pancreatic ductal adenocarcinoma (PDA).  PDA is considered the deadliest of major cancers and patients are in desperate need of improved therapies. PDA is caused by chronic inflammatory stress associated with the increasingly common afflictions of obesity, type 2 diabetes, and pancreatitis, exacerbated by smoking and drinking.  KPC34 is a candidate therapeutic because it is activated preferentially inside tumor cells to release an inhibitor of DNA replication and a separate tumor promotion inhibitor. Annually, more than 350,000 new cases of pancreatic cancer are diagnosed across the world.  According to the American Society of Clinical Oncology, a six-month course of gemcitabine, the chemotherapy drug typically used to treat advanced pancreatic cancer, costs about $23,500.

  • ACCESSWIRE8 months ago

    Today's Research Reports on Trending Tickers: Twilio and Spherix

    NEW YORK, NY / ACCESSWIRE / November 27, 2018 / Twilio shares were on the rise on an “outperform” rating reiterated from an Oppenheimer analyst last week while Spherix Incorporated shares popped on news ...

  • Spherix Announces Ownership Interest in Electric Scooter Business
    PR Newswire8 months ago

    Spherix Announces Ownership Interest in Electric Scooter Business

    From renting out an unused road bike, to running a fleet of hundreds of electric scooters, Mellow provides a flexible entry for anyone interested in the growing shared vehicles space. Additional information about the investment will be available in the Form 8-K, filed by Spherix with the Securities and Exchange Commission.

  • Spherix Announces the Addition of Dr. Rana Quraishi to Company's Advisory Board
    PR Newswire9 months ago

    Spherix Announces the Addition of Dr. Rana Quraishi to Company's Advisory Board

    NEW YORK, Oct. 29, 2018 /PRNewswire/ -- Spherix Incorporated (SPEX) today announced that it has added Dr. Rana Quraishi to the Company's Advisory Board to assist the Company in evaluating potential opportunities in the biopharmaceutical area. Dr. Rana Quraishi is the Director of New Ventures, at UM Ventures University of Maryland, Baltimore.  UM Ventures is a joint initiative bringing the University of Maryland, Baltimore and University of Maryland, College Park together to commercialize discoveries and create economic impact by engaging partners in industry and social ventures.  Dr. Quraishi has a Ph.D. in Molecular Biology and Biochemistry from Columbia University where she was also an undergraduate and an M.S. from Harvard University.

  • Newsfile9 months ago

    StockLab Reports: Of Mice and Men

    Las Vegas, Nevada--(Newsfile Corp. - October 25, 2018) - Early stage biotechnology and pharmaceutical companies often present a quandary for investors. The technology is generally difficult to understand and investors just can't fully picture the potential.Except when that picture is an absolutely stunning, must-see video from Wake Forest University of a mouse paralyzed by Acute Lymphoblastic Leukemia restored to mobility in two days by a drug now headed to the patent portfolio of ...

  • Spherix Provides Video Demonstration of CBM Drug Reversing Paralysis in Preclinical Study
    PR Newswire9 months ago

    Spherix Provides Video Demonstration of CBM Drug Reversing Paralysis in Preclinical Study

    Anthony Hayes, CEO of Spherix, stated, "This remarkable video demonstrates the tremendous potential for this drug to treat ALL.  The video was part of a written submission on KPC34 to PLOS OneTM a peer reviewed medical journal.

  • Spherix to Merge with CBM BioPharma Pharmaceutical Company
    PR Newswire9 months ago

    Spherix to Merge with CBM BioPharma Pharmaceutical Company

    NEW YORK, Oct. 11, 2018 /PRNewswire/ -- Spherix Incorporated (SPEX) today announced that it has entered into a merger agreement with CBM BioPharma, Inc. ("CBM") that will transform Spherix into an innovative pharmaceutical company with pioneering drugs and treatments focused on the multibillion dollar oncology therapeutics market. CBM is a privately held pharmaceutical company with exclusive drug development rights from world-renowned partners including Wake Forest Innovations and the University of Texas at Austin. CBM has a team of leading drug development scientists who will be joining Spherix as advisors to advance the technology.

  • Spherix Announces Strategic Equity Investment in DatChat in Lieu of Full Company Merger
    PR Newswire11 months ago

    Spherix Announces Strategic Equity Investment in DatChat in Lieu of Full Company Merger

    NEW YORK, Aug. 15, 2018 /PRNewswire/ -- Spherix Incorporated (SPEX) a technology development company committed to the fostering of innovation and monetization of intellectual property, today announced it has terminated its merger agreement with DatChat. After strategic meetings with DatChat, both organziations believe there is a more effective strategy that will have the best opportunity for long-term growth. The Spherix Board of Directors determined that a strategic equity investment in DatChat will provide a better strategy for shareholders and allow Spherix to benefit from DatChat's platform and projected growth.